Simple urine test could revolutionize DMD drug trials

NCT ID NCT07332013

Recruiting now Knowledge-focused Sponsor: Children's Hospital of Philadelphia Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether a protein called titin, found in urine, can serve as a reliable marker of muscle injury in people with Duchenne or Becker muscular dystrophy. Researchers will measure titin levels before and after activities like walking down stairs, and track daily activity with wearable sensors. The goal is to develop a non-invasive biomarker that could make future clinical trials smaller, faster, and more informative.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could provide a simple urine test to track muscle damage in DMD, making future drug trials faster and more accurate.
What could go wrong: This is an early observational study with only 50 participants, so the biomarker may not prove reliable enough for widespread use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BECKER'S MUSCULAR DYSTROPHY (BMD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Becker muscular dystrophy Duchenne muscular dystrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BECKER'S MUSCULAR DYSTROPHY (BMD) DUCHENNE MUSCULAR DYSTROPHY (DMD)

Contacts and locations

Locations

Children's Hospital of Philadelphia
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.